Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs IONQ Inc (IONQ) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs IONQ Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.67 (market cap $5.07B), while IONQ Inc trades at $44.75 (market cap $17.60B). The key difference: IONQ Inc is far larger — about 3.5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.

ACADIONQ
Market Cap
$5.07B$17.60B
Sector
HealthTechnology
52-Week High
$29.41$82.09
52-Week Low
$20.06$26.59
Enterprise Value
$4.19B$15.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

IONQ Inc

IONQ trades at $43.92, up 3.27% today, with a bullish technical signal and strong revenue growth of 287% in Q2 2026. Despite significant net losses and negative margins, the company's backlog surged to $485 million, and it secured a $28 million defense contract extension. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism about its quantum computing leadership.

Outlook: High growth potential in quantum computing with raised 2026 revenue guidance, but profitability remains distant. Risks include heavy cash burn, intense competition, and stock volatility. The stock offers speculative upside for growth investors tolerant of high risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About IONQ Inc

IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.

Read more on IONQ